We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First Thyroid Cancer-Specific Anxiety Scale Supports Patient-Centered Care

By HospiMedica International staff writers
Posted on 09 Sep 2026

Thyroid cancer care can range from active surveillance to total thyroidectomy, leaving many patients to navigate difficult treatment choices. More...

Anxiety about monitoring, prognosis, and recurrence can shape these preferences and complicate shared decision-making. Clinicians therefore need structured ways to identify and address disease-specific distress. In response, investigators have developed a targeted instrument to measure thyroid cancer-related anxiety and support more individualized care.

The Thyroid Cancer Modified Anxiety Scale (TC-MAX) was developed by Cedars-Sinai Health Sciences University and is described as the first tool designed specifically to measure anxiety in patients with thyroid cancer. The tool aims to clarify patient expectations, helping clinicians better align treatment intensity with individual needs and support improved outcomes.

TC-MAX uses 18 questions to assess three domains. It measures general cancer-related anxiety, anxiety related to ultrasound testing used to monitor disease progression, and fear of progression or recurrence. Development involved collaboration with the Thyroid Cancer Survivors’ Association, drawing on medical literature, physician expertise, and the perspectives of more than 1,000 thyroid cancer patients.

In study findings, patient anxiety scores tracked with the extent of surgery chosen when multiple options were clinically reasonable. Patients with the highest TC-MAX scores tended to select total thyroid removal, those with lower average scores more often chose partial thyroid removal, and those with the lowest scores typically opted for active surveillance. Investigators reported that the tool is ready for use in clinical trials and patient care.

The work was published in Thyroid on August 11, 2026.

“A patient’s distress greatly influences which thyroid cancer treatment the patient prefers and what their doctor recommends,” said Allen Ho, MD, professor of surgery, co-director of the Thyroid Cancer Program at Cedars-Sinai Cancer and senior author of the study.

“We found that our tool effectively assesses patient concerns to help doctors better determine the best course of treatment. This is especially important when treatment options have similar likely outcomes but patient preferences vary widely,” Ho said.

Related Links
Cedars-Sinai Health Sciences University


Gold Member
Blood Gas Analyzer
i-Check200
Gold Member
12-Channel ECG
CM1200B
Pediatric Mask
Respire SOFT
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.